Prevention and treatment of amyloid-associated disorders

a technology of amyloid plaques and amyloid-associated disorders, which is applied in the field of neurological diseases involving amyloid plaque formation, can solve the problems that cerebrovascular arnyloid deposits may interfere with cognitive functions, and achieve narrowly tailored therapeutic agents and fewer general side effects

Inactive Publication Date: 2006-09-21
SCIOS
View PDF10 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0026] An advantage of the invention is that the assays of the invention can identify therapeutic agents that target a specific pathway, and thus have fewer general side effects.
[0027] Another advantage of the invention is that it provides more narrowly tailored therapeutic agents. In particular, since human microglia do not express EP3, therapeutics can be used that do not have side effects associated with targeting EP3.

Problems solved by technology

In some familial CAA cases, dementia was noted before the onset of hemorrhages, suggesting the possibility that cerebrovascular arnyloid deposits may also interfere with cognitive functions.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Prevention and treatment of amyloid-associated disorders
  • Prevention and treatment of amyloid-associated disorders
  • Prevention and treatment of amyloid-associated disorders

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation and Characterization of Primary Glia Cell Cultures

[0088] As co-culture with astrocytes is known to promote the resting state for cultured microglia, mixed primary glial cultures are a particularly suitable system in which to examine PGE2:Aβ synergy. Briefly, cortices from P3 wild type mice were dissected in Ca2+ and Mg2+ free HBSS (Gibco). Meninges were carefully dissected away, and the tissue transferred to a dish containing HBSS supplemented with 0.53 mM EDTA and 0.05% trypsin. The tissue was incubated for 18 minutes at. room temperature with occasional gentle agitation. Trypsin was removed and the tissue washed with HBSS twice prior to titration in growth medium consisting of high glucose DMEM supplemented with 10% fetal bovine serum (FBS), 110 mg / L sodium pyruvate, and 5 units / ml penicillin / streptomycin. The cell suspension was plated at 9 cortices in growth medium into one T75 and one T25 flask. The next day, nonadherent cells were removed. The culture was refed wi...

example 2

Aβ:PGE2 Synergy Experiments in Primary Mixed Glial Cells

[0093] Endogenous PGE2 levels and the ability of indomethacin to suppress PGE2 were investigated by assaying medium conditioned by mature (confluent) primary mixed murine glial cultures in 48 well plates for 48 hours. Under basal conditions, PGE2 was observed at just under 200 pg / ml conditioned media, in keeping with literature reports for primary cultures. Exposure to 100 ng / ml LPS dramatically increased this level to a concentration that saturated the assay at medium dilutions used, demonstrating the ability of the cultures to respond robustly to stimulus. Treatment of the cultures during the conditioning.period with 14 μM indomethacin suppressed PGE2 secretion to about 30 pg / ml in 48 hours. This is within the range in which would allow PGE2:Aβ synergy to be observed.

[0094] The effect of Aβ in the presence and absence of exogenous PGE2 was investigated in these primary cortical mixed glial cultures. An Aβ peptide was resusp...

example 3

Aβ:PGE2 Synergy Experiments in MMGT-16 Mouse Microglial Cell Culture

[0097] The protocol described above in Example 2 was then used to examine the synergy between PGE2 and Aβ in the mouse microglial cell line MMGT-16.

[0098] Synergy in MMGT-16 cells was examined by measuring secretion of both TNF-α (FIG. 4) and IL-1β (FIG. 5). The secretion of IL-1β was unaffected by the addition of either PGE2 or Aβ alone, while addition of both resulted in a dramatic increase in the secretion of IL-1β. PGE2 had no discernable effect on TNF-α secretion as well, while Aβ alone had a modest affect on TNF-α secretion. The addition of both Aβ and TNF-α together, however, resulted in a synergistic increase in the secretion of TNF-α

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
weightaaaaaaaaaa
timeaaaaaaaaaa
Login to view more

Abstract

The present invention provides assays to identify compounds that affect microglial cell activation, and specifically assays to identify compounds that affect secretion of cytokines from these microglial cells by modulating PGE2-mediated activity. The assays of the invention include assays for testing microglial cell activation by contacting microglia with compounds that modulate β-amyloid PGE2-mediated activation, which can be identified by cellular activity such as secretion of cytokines, e.g., TNF-α and IL-1α,. The effect of the candidate compound can be determined by comparing the effect with a control culture which is not contacted with the compound, or by comparing the effect with a standardized profile.

Description

CROSS-REFERENCE [0001] This application claims priority to U.S. provisional application Ser. No. 60 / 142,175, filed Jul. 1, 1999, which application is incorporated herein by reference in its entirety.FIELD OF THE INVENTION [0002] The invention relates generally to the treatment of neurological diseases and specifically to treatment of neurological diseases involving amyloid plaque formation. BACKGROUND OF THE INVENTION [0003] A number of important neurological diseases including Alzheimer's disease (AD), cerebral amyloid angiopathy (CAA), and prion-mediated diseases are characterized by the deposition of aggregated proteins, referred to as amyloid, in the central nervous system (CNS) (for reviews, see Glenner et al. (1989) J. Neurol. Sci. 94:1-28; Haan et al. (1990) Clin. Neurol. Neurosurg. 92(4):305-310. These highly insoluble aggregates are composed of nonbranching, fibrillar proteins with the common characteristic of a β-pleated sheet conformation. In the CNS, amyloid can be prese...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C12Q1/00G01N33/567A61K45/00A61P25/28C12Q1/02G01N33/15G01N33/50G01N33/68
CPCG01N33/5008G01N33/502G01N33/5026G01N33/5041G01N33/5044G01N33/5047G01N33/5058G01N33/6863G01N33/6896G01N2333/4709G01N2800/2821A61P25/28
Inventor HYSLOP, PAULMILLER, FOYHIGGINS, LINDACATALANO, ROSANNECORDELL, BARBARAPUCHACZ, ELZBIETA
Owner SCIOS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap